Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 23;6(12):3707–3715. doi: 10.1182/bloodadvances.2022007296

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

PMC Copyright notice

Figure 2. — Long-term outcomes for risk groups in the validation cohort defined by 2 biomarker algorithms. We identified high-risk (HR; red) and low-risk (LR; blue) groups for patients in the validation cohort (n = 378) using optimal thresholds that we defined in the training cohort: (A) TNFR1 + TIM3, (B) ST2 + REG3α, (C) TNFR1 + ST2, and (D) TNFR1 + REG3α. Left panel: the proportion of steroid-treated patients with a CR or PR at day 28. Middle panel: cumulative incidence of 6-month NRM. Right panel: overall survival in the first 6 months.